Channing Capital Management LLC acquired a new stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 82,148 shares of the medical equipment provider’s stock, valued at approximately $9,619,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of ZBH. Bronfman E.L. Rothschild L.P. grew its holdings in Zimmer Biomet Holdings by 25.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 167 shares during the period. Parkside Financial Bank & Trust boosted its holdings in shares of Zimmer Biomet Holdings by 3.9% in the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock valued at $112,000 after buying an additional 33 shares during the period. Parallel Advisors LLC boosted its holdings in shares of Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares during the period. IHT Wealth Management LLC boosted its holdings in shares of Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares during the period. Finally, BB&T Investment Services Inc. acquired a new position in shares of Zimmer Biomet Holdings in the second quarter valued at approximately $144,000. Hedge funds and other institutional investors own 85.26% of the company’s stock.
Zimmer Biomet Holdings Inc (NYSE:ZBH) traded down $5.84 during mid-day trading on Friday, hitting $109.25. 3,876,137 shares of the company traded hands, compared to its average volume of 1,446,411. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.80. Zimmer Biomet Holdings Inc has a fifty-two week low of $95.63 and a fifty-two week high of $133.49. The firm has a market capitalization of $22.09 billion, a P/E ratio of 13.92, a PEG ratio of 1.53 and a beta of 1.17.
Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. During the same quarter last year, the firm posted $1.79 EPS. The firm’s revenue for the quarter was down .8% on a year-over-year basis. equities research analysts anticipate that Zimmer Biomet Holdings Inc will post 8.03 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, October 27th. Stockholders of record on Friday, September 22nd were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date of this dividend was Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is currently 29.91%.
ZBH has been the subject of several research analyst reports. BMO Capital Markets reiterated a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet Holdings in a report on Tuesday, July 11th. Wells Fargo & Company reiterated a “market weight” rating on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Morgan Stanley upped their price target on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, July 17th. Stifel Nicolaus restated a “hold” rating and set a $125.00 target price on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Finally, Zacks Investment Research cut shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of $134.75.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
What are top analysts saying about Zimmer Biomet Holdings Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc and related companies.